09.26.24 -- FDA Finalizes Guidance On Dose Optimization For Oncology Therapies

Gain access to strategic insights for clinical trial sponsors on targeting an orphan drug designation and the logistical considerations involved in pursuing this path from the outset.

Explore the practical implications faced by investigators and their support staff, such as navigating new bureaucratic procedures and adhering to revised regulatory requirements.

Support your local safety needs and drive consistency with global requirements through end-to-end solutions with regulatory-focused medical experts and leading technologies.

In part two of this webinar series, presenters focus on avoiding potential risks, such as unexpected budget changes and unplanned change orders, which could jeopardize the success of a clinical trial.

Leveraging a CDMO to oversee all aspects of analytical method development is crucial for achieving speed in clinical trials, regulatory approval, and commercial launch.

Uncover the detailed outcomes of this extensive Phase 3 clinical trial on a new biosimilar for non-small cell lung cancer.

Discover the key PV RI capabilities that pharma, biotech, and medical device companies are adopting to ensure comprehensive and cost-effective strategies.

Altasciences’ clinical facilities are integrated with state-of-the-art flow cytometry laboratories. We are equipped with advanced platforms and staffed by a dedicated team of in-house experts.

Partner with us to co-create strategies and achieve operational excellence with our FSP capabilities, providing value as an extension of your team to advance your development programs.